E-Mail
Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed.
The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.
The Phase I study, led by a researcher at NYU Langone Health and its Perlmutter Cancer Center, is also among the first to show how such oncolytic viruses can safely boost the action of widely used cancer therapies that help the body s immune defense system detect and kill cancer cells. Currently, such immunotherapies are only effective in shrinking melanoma tumors in just over a third of patients who receive them.
Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Published 01 April 2021
Adjuvant therapy trials for urothelial carcinoma have traditionally been challenging to perform. Radical cystectomy is a significantly morbid procedure that leads to high complication and readmission rates. Hence, many patients are not fit to receive any adjuvant therapy after definitive local therapy due to a compromised health situation. At this time, neoadjuvant chemotherapy is still the definitive standard.
1 However, not all patients receive neoadjuvant therapy for a multitude of reasons. For those who did not receive neoadjuvant cisplatin combination chemotherapy, common sense warrants strong consideration of adjuvant therapy as long as a patient is fit and interested.
However, we have extremely limited evidence on what to do if a patient has residual muscle invasive disease after prior receipt of neoadjuvant combination cisplatin-based chemotherapy. This is clearly an unmet need population due to the very poor prognosis.